ECSP066992A - ÁCIDO 2-{[2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBONIL]AMINO}-3-(FENILPIRIDIN-2-ILAMINO)PROPIÓNICOSUSTANCIALMENTE PURO COMO INHIBIDOR DE LA CINASA IkB - Google Patents

ÁCIDO 2-{[2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBONIL]AMINO}-3-(FENILPIRIDIN-2-ILAMINO)PROPIÓNICOSUSTANCIALMENTE PURO COMO INHIBIDOR DE LA CINASA IkB

Info

Publication number
ECSP066992A
ECSP066992A EC2006006992A ECSP066992A ECSP066992A EC SP066992 A ECSP066992 A EC SP066992A EC 2006006992 A EC2006006992 A EC 2006006992A EC SP066992 A ECSP066992 A EC SP066992A EC SP066992 A ECSP066992 A EC SP066992A
Authority
EC
Ecuador
Prior art keywords
inhibitor
phenylpiridin
methylaminopirimidin
ilamino
indol
Prior art date
Application number
EC2006006992A
Other languages
English (en)
Inventor
Olaf Ritzeler
El-Bdaoui Haddad
David John Aldous
Paul Joseph Cox
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ECSP066992A publication Critical patent/ECSP066992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida al compuesto sustancialmente puro de fórmula (A), (A)o una sal farmacéuticamente aceptable, o solvato de dicho compuesto; a una composición farmacéutica que comprende una cantidad farmacéuticamente eficaz del compuesto de fórmula (A), y un vehículo farmacéuticamente aceptable; y al uso de un compuesto de fórmula (A) que tiene actividad como inhibidor, preferiblemente un inhibidor selectivo, de IkB (IKK), en particular IKK-2, y a métodos relacionados con ello.
EC2006006992A 2004-05-12 2006-11-10 ÁCIDO 2-{[2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBONIL]AMINO}-3-(FENILPIRIDIN-2-ILAMINO)PROPIÓNICOSUSTANCIALMENTE PURO COMO INHIBIDOR DE LA CINASA IkB ECSP066992A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12

Publications (1)

Publication Number Publication Date
ECSP066992A true ECSP066992A (es) 2006-12-29

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006992A ECSP066992A (es) 2004-05-12 2006-11-10 ÁCIDO 2-{[2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBONIL]AMINO}-3-(FENILPIRIDIN-2-ILAMINO)PROPIÓNICOSUSTANCIALMENTE PURO COMO INHIBIDOR DE LA CINASA IkB

Country Status (23)

Country Link
EP (1) EP1747215A1 (es)
JP (1) JP2007537266A (es)
KR (1) KR20070011483A (es)
CN (1) CN1950359A (es)
AR (1) AR049274A1 (es)
AU (1) AU2005245834A1 (es)
BR (1) BRPI0511029A (es)
CA (1) CA2566213A1 (es)
EC (1) ECSP066992A (es)
GT (1) GT200500111A (es)
IL (1) IL178992A0 (es)
MA (1) MA28553B1 (es)
MX (1) MXPA06012870A (es)
NO (1) NO20065719L (es)
PA (1) PA8633101A1 (es)
PE (1) PE20060269A1 (es)
RU (1) RU2006143758A (es)
SV (1) SV2006002111A (es)
TN (1) TNSN06338A1 (es)
TW (1) TW200605881A (es)
UY (1) UY28897A1 (es)
WO (1) WO2005113544A1 (es)
ZA (1) ZA200608712B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20130069641A (ko) * 2010-04-27 2013-06-26 허치슨 메디파르마 리미티드 피리미디닐 인돌 화합물
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
CN106588803A (zh) * 2016-11-16 2017-04-26 西南科技大学 一种制备5‑乙酰基异噁唑的新方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
JP2007537266A (ja) 2007-12-20
IL178992A0 (en) 2007-03-08
BRPI0511029A (pt) 2007-11-27
CN1950359A (zh) 2007-04-18
RU2006143758A (ru) 2008-06-27
SV2006002111A (es) 2006-01-30
GT200500111A (es) 2006-05-09
AU2005245834A1 (en) 2005-12-01
PE20060269A1 (es) 2006-05-11
ZA200608712B (en) 2008-06-25
NO20065719L (no) 2006-12-12
TW200605881A (en) 2006-02-16
EP1747215A1 (en) 2007-01-31
AR049274A1 (es) 2006-07-12
CA2566213A1 (en) 2005-12-11
MA28553B1 (fr) 2007-04-03
PA8633101A1 (es) 2006-01-23
WO2005113544A1 (en) 2005-12-01
KR20070011483A (ko) 2007-01-24
UY28897A1 (es) 2005-12-30
MXPA06012870A (es) 2007-02-15
TNSN06338A1 (en) 2008-02-22

Similar Documents

Publication Publication Date Title
UY28897A1 (es) Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
ECSP11010948A (es) Inhibidores de las enzimas de proteína cinasa activadas por
EA200800670A1 (ru) Ингибиторы сериновых протеаз
CO6231036A2 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
EA200700192A1 (ru) Производные фталазина в качестве ингибиторов parp
NO20091846L (no) Makrocykliske peptider som hepatitt C virus- inhibitorer
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
BRPI0508085A (pt) compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c
UY32062A (es) Inhibidores de beta-secretasa
EA200900676A1 (ru) Ингибиторы вируса гепатита с
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
AR056764A1 (es) Aminopirimidinas utiles como inhibidores de quinasa
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
BRPI0507972A (pt) composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada
EA200800240A1 (ru) Производные тиазола в качестве активатора амфк
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
ECSP088965A (es) Derivados de 2-tioxantina que actúan como inhibidores de la mpo
UY30941A1 (es) Inhibidores de serina proteasas
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors